Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome

Science Translational Medicine

Volumn 4, Issue 131, 2012, Pages

  Lu, Zhongju ^a   Wu, Chia Yen C ^a   Jiang, Ya Ping ^a   Ballou, Lisa M ^a   Clausen, Chris ^a   Cohen, Ira S ^a   Lin, Richard Z ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; DASATINIB; IMATINIB; MEXILETINE; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PROTEIN P110; PROTEIN P110 ALPHA; PROTEIN TYROSINE KINASE; SUNITINIB; TERFENADINE; UNCLASSIFIED DRUG; CALCIUM CHANNEL L TYPE; DELAYED RECTIFIER POTASSIUM CHANNEL; PHOSPHATIDYLINOSITOL 3,4,5-TRIPHOSPHATE; PIK3CA PROTEIN, MOUSE; PIK3CB PROTEIN, MOUSE; POLYPHOSPHOINOSITIDE; PROTEIN KINASE INHIBITOR; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ACTION POTENTIAL DURATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CALCIUM CURRENT; CARDIOVASCULAR RISK; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELAYED RECTIFIER POTASSIUM CURRENT; DISEASE ASSOCIATION; DOG; DOWN REGULATION; DRUG EFFECT; DRUG INDUCED DISEASE; EARLY AFTER DEPOLARIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; FEMALE; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; ION CURRENT; ISOLATED HEART; L TYPE CALCIUM CURRENT; LONG QT SYNDROME; MALE; MOUSE; NONHUMAN; PERSISTENT SODIUM CURRENT; POTASSIUM CURRENT; PRIORITY JOURNAL; QT PROLONGATION; SIGNAL TRANSDUCTION; SODIUM CURRENT; ACTION POTENTIAL; ANIMAL; BIOLOGICAL MODEL; CHEMICALLY INDUCED DISORDER; COMPUTER SIMULATION; DRUG ANTAGONISM; ELECTROCARDIOGRAPHY; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; RISK ASSESSMENT; TIME;

ACTION POTENTIALS; ANIMALS; CALCIUM CHANNELS, L-TYPE; COMPUTER SIMULATION; DELAYED RECTIFIER POTASSIUM CHANNELS; DOGS; ELECTROCARDIOGRAPHY; FEMALE; LONG QT SYNDROME; MALE; MICE; MICE, KNOCKOUT; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHATIDYLINOSITOL PHOSPHATES; PROTEIN KINASE INHIBITORS; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TIME FACTORS;

EID: 84860376625     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003623     Document Type: Article

References (41)

1. P. L. Hedley, P. Jørgensen, S. Schlamowitz, R. Wangari, J. Moolman-Smook, P. A. Brink, J. K. Kanters, V. A. Corfield, M. Christiansen, The genetic basis of long QT and short QT syndromes: A mutation update. Hum. Mutat. 30, 1486-1511 (2009).
2. P. J. Mohler, J. J. Schott, A. O. Gramolini, K. W. Dilly, S. Guatimosim, W. H. duBell, L. S. Song, K. Haurogné, F. Kyndt, M. E. Ali, T. B. Rogers, W. J. Lederer, D. Escande, H. LeMarec, V. Bennett, Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 421, 634-639 (2003).
3. D. M. Roden, Drug-induced prolongation of the QT interval. N. Engl. J. Med. 350, 1013-1022 (2004).
4. The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, 2005).
5. J. S. Mitcheson, hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem. Res. Toxicol. 21, 1005-1010 (2008).
6. J. S. Mitcheson, J. Chen, M. C. Sanguinetti, Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol. 115, 229-240 (2000).
7. E. Ficker, Y. A. Kuryshev, A. T. Dennis, C. Obejero-Paz, L. Wang, P. Hawryluk, B. A. Wible, A. M. Brown, Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol. Pharmacol. 66, 33-44 (2004).
8. Y. A. Kuryshev, E. Ficker, L. Wang, P. Hawryluk, A. T. Dennis, B. A. Wible, A. M. Brown, J. Kang, X. L. Chen, K. Sawamura, W. Reynolds, D. Rampe, Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 312, 316-323 (2005).
9. A. Dennis, L. Wang, X. Wan, E. Ficker, hERG channel trafficking: Novel targets in drug-induced long QT syndrome. Biochem. Soc. Trans. 35, 1060-1063 (2007).
10. M. Agrawal, R. J. Garg, J. Cortes, A. Quintás-Cardama, Tyrosine kinase inhibitors: The first decade. Curr. Hematol. Malig. Rep. 5, 70-80 (2010).
11. V. R. Adams, M. Leggas, Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin. Ther. 29, 1338-1353 (2007).
12. J. M. Backer, M. G. Myers Jr., S. E. Shoelson, D. J. Chin, X. J. Sun, M. Miralpeix, P. Hu, B. Margolis, E. Y. Skolnik, J. Schlessinger, M. F. White, Phosphatidylinositol 3?-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J. 11, 3469-3479 (1992).
13. C. L. Carpenter, K. R. Auger, M. Chanudhuri, M. Yoakim, B. Schaffhausen, S. Shoelson, L. C. Cantley, Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J. Biol. Chem. 268, 9478-9483 (1993).
14. N. D. Skadsberg, A. J. Hill, P. A. Iaizzo, Isolated heart models, in Cardiac Electrophysiology Methods and Models, D. C. Sigg, P. A. Iaizzo, Y.-F. Xiao, B. He, Eds. (Springer, New York, 2010), pp. 249-260.
15. W. S. Redfern, L. Carlsson, A. S. Davis, W. G. Lynch, I. MacKenzie, S. Palethorpe, P. K. Siegl, I. Strang, A. T. Sullivan, R. Wallis, A. J. Camm, T. G. Hammond, Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45 (2003).
16. S. M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers, C. Garcia-Echeverria, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
17. F. I. Raynaud, S. Eccles, P. A. Clarke, A. Hayes, B. Nutley, S. Alix, A. Henley, F. Di-Stefano, Z. Ahmad, S. Guillard, L. M. Bjerke, L. Kelland, M. Valenti, L. Patterson, S. Gowan, A. de Haven Brandon, M. Hayakawa, H. Kaizawa, T. Koizumi, T. Ohishi, S. Patel, N. Saghir, P. Parker, M. Waterfield, P. Workman, Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67, 5840-5850 (2007).
18. W. J. Freebern, H. S. Fang, M. D. Slade, S. Wells, J. Canale, J. Megill, B. Grubor, H. Shi, A. Fletcher, L. Lombardo, P. Levesque, F. Y. Lee, V. G. Sasseville, In vitro cardiotoxicity potential comparative assessments of chronic myelogenous leukemia tyrosine kinase inhibitor therapies: Dasatinib, imatinib and nilotinib. Blood 110, abstract 4582 (2007).
19. Z. Lu, Y. P. Jiang, W. Wang, X. H. Xu, R. T. Mathias, E. Entcheva, L. M. Ballou, I. S. Cohen, R. Z. Lin, Loss of cardiac phosphoinositide 3-kinase p110α results in contractile dysfunction. Circulation 120, 318-325 (2009).
20. T. J. Hund, Y. Rudy, Rate dependence and regulation of action potential and calcium transient in a canine cardiac ventricular cell model. Circulation 110, 3168-3174 (2004).
21. G. R. Mirams, Y. Cui, A. Sher, M. Fink, J. Cooper, B. M. Heath, N. C. McMahon, D. J. Gavaghan, D. Noble, Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc. Res. 91, 53-61 (2011).
22. B. P. Monahan, C. L. Ferguson, E. S. Killeavy, B. K. Lloyd, J. Troy, L. R. Cantilena Jr., Torsades de pointes occurring in association with terfenadine use. JAMA 264, 2788-2790 (1990).
23. H. Sun, G. Y. Oudit, R. J. Ramirez, D. Costantini, P. H. Backx, The phosphoinositide 3-kinase inhibitor LY294002 enhances cardiac myocyte contractility via a direct inhibition of Ik,slow currents. Cardiovasc. Res. 62, 509-520 (2004).
24. G. Y. Oudit, H. Sun, B. G. Kerfant, M. A. Crackower, J. M. Penninger, P. H. Backx, The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol. 37, 449-471 (2004).
25. S. L. Cockerill, A. B. Tobin, I. Torrecilla, G. B. Willars, N. B. Standen, J. S. Mitcheson, Modulation of hERG potassium currents in HEK-293 cells by protein kinase C. Evidence for direct phosphorylation of pore forming subunits. J. Physiol. 581, 479-493 (2007).
26. Y. Zhang, H. Wang, J. Wang, H. Han, S. Nattel, Z. Wang, Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activity. FEBS Lett. 534, 125-132 (2003).
27. P. Viard, A. J. Butcher, G. Halet, A. Davies, B. Nurnberg, F. Heblich, A. C. Dolphin, PI3K promotes voltage-dependent calcium channel trafficking to the plasma membrane. Nat. Neurosci. 7, 939-946 (2004).
28. N. Strutz-Seebohm, U. Henrion, K. Steinke, D. Tapken, F. Lang, G. Seebohm, Serum- and glucocorticoid-inducible kinases (SGK) regulate KCNQ1/KCNE potassium channels. Channels 3, 88-90 (2009).
29. G. Salama, B. London, Mouse models of long QT syndrome. J. Physiol. 578, 43-53 (2007).
30. F. Charpentier, A. Bourgé, J. Mérot, Mouse models of SCN5A-related cardiac arrhythmias. Prog. Biophys. Mol. Biol. 98, 230-237 (2008).
31. D. Nuyens, M. Stengl, S. Dugarmaa, T. Rossenbacker, V. Compernolle, Y. Rudy, J. F. Smits, W. Flameng, C. E. Clancy, L. Moons, M. A. Vos, M. Dewerchin, K. Benndorf, D. Collen, E. Carmeliet, P. Carmeliet, Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome. Nat. Med. 7, 1021-1027 (2001).
32. X. L. Tian, S. L. Yong, X. Wan, L. Wu, M. K. Chung, P. J. Tchou, D. S. Rosenbaum, D. R. Van Wagoner, G. E. Kirsch, Q. Wang, Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo. Cardiovasc. Res. 61, 256-267 (2004).
33. P. J. Schwartz, S. G. Priori, E. H. Locati, C. Napolitano, F. Cantù, J. A. Towbin, M. T. Keating, H. Hammoude, A. M. Brown, L. S. Chen, Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 92, 3381-3386 (1995).
34. E. T. Yeh, C. L. Bickford, Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53, 2231-2247 (2009).
35. H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O' Brien, B. Wassmann, C. Tanaka, P. Manley, P. Rae, W. Mietlowski, K. Bochinski, A. Hochhaus, J. D. Griffin, D. Hoelzer, M. Albitar, M. Dugan, J. Cortes, L. Alland, O. G. Ottmann, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354, 2542-2551 (2006).
36. J. D. Peyton, J. Rodon Ahnert, H. Burris, C. Britten, L. C. Chen, J. Tabernero, V. Duval, N. Rouyrre, A. Silva, C. Quadt, J. Baselga, A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. J. Clin. Oncol. 29 (May 20 Supplement), abstract 3066 (2011).
37. G. Fan, Y. P. Jiang, Z. Lu, D. W. Martin, D. J. Kelly, J. M. Zuckerman, L. M. Ballou, I. S. Cohen, R. Z. Lin, A transgenic mouse model of heart failure using inducible Gαq. J. Biol. Chem. 280, 40337-40346 (2005).
38. L. Wang, H. J. Duff, Developmental changes in transient outward current in mouse ventricle. Circ. Res. 81, 120-127 (1997).
39. G. F. Mitchell, A. Jeron, G. Koren, Measurement of heart rate and Q-T interval in the conscious mouse. Am. J. Physiol. 274, H747-H751 (1998).
40. L. M. Ballou, M. E. Cross, S. Huang, E. M. McReynolds, B. X. Zhang, R. Z. Lin, Differential regulation of the phosphatidylinositol 3-kinase/Akt and p70 S6 kinase pathways by the α1A-adrenergic receptor in rat-1 fibroblasts. J. Biol. Chem. 275, 4803-4809 (2000).
41. D. H. Lau, C. Clausen, E. A. Sosunov, I. N. Shlapakova, E. P. Anyukhovsky, P. Danilo Jr., T. S. Rosen, C. Kelly, H. S. Duffy, M. J. Szabolcs, M. Chen, R. B. Robinson, J. Lu, S. Kumari, I. S. Cohen, M. R. Rosen, Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: An in silico, in vivo, in vitro study. Circulation 119, 19-27 (2009).